Doctors take on Highmark on office-visit drug co-pays
Pittsburgh Post-Gazette, March 7, 2008
Highmark Inc.'s recent decision to charge Medicare customers $25 co-payments on certain injected drugs--chemotherapy agents, immunosuppressants, anemia drugs--is becoming a financial burden to a number of customers who require such injections several times a week. A spokesman for Highmark said the new charges were needed to defray the rising cost of the injected drugs, which can run from $100 to $30,000 per dose, depending on the drug.
Most Viewed
Most Emailed
- Healthcare Leaders Seek Strategic Sweet Spot
- 3 Reasons Wellness Programs Fail
- CMS Issues Health Insurance Exchange Proposed Rules
- Patients Shoulder Nearly 25% of Medical Bills
- ACOs Widespread, Yet Challenged
- MGMA: Physician Compensation Increasingly Based on Quality Measures
- 6 CNO-to-CEO Strategies
- HFMA: Patient Financial Interaction Guidelines Sharpened
- PwC: Pace of Rising Medical Costs Slowing
- Hacking Healthcare is Fred Trotter's Passion
